BioCentury
ARTICLE | Politics & Policy

Brexit delay offers biopharma more time to prepare for a no-deal

March 22, 2019 6:12 PM UTC

Although Europe remains at risk of a drug supply disruption in the event of a no-deal Brexit, Thursday's extension means more time for British biopharma companies to get drug applications approved, and for the U.K. and EU to address supply chain concerns.

EU President Donald Tusk announced an agreement yesterday to extend the deadline for EU withdrawal to May 22 if the U.K. Parliament can approve an exit deal next week -- although it rejected a negotiated agreement on March 12. If Parliament does not approve the deal, Tusk said a no-deal exit would take place on April 12 (see “After May’s Second Defeat, ABPI Calls on Parliament to Avoid No-Deal Brexit”)...